2023
SLAC Social Leverage Acquisition Corp I
CNNXF Cannamerica Brands Corp
BA Boeing Co
Go

TransCode Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing drugs for treating metastatic disease. The Company’s development pipeline includes TTX-MC138, TTX-siPD-L1 and TTX-RIGA, TTX-siLIN28B, and TCD-miR10b. The Company has developed a modular, iron oxide nanoparticle-based nanocarrier system for the delivery of RNA therapeutics to tumors. The Company’s lead therapeutic candidate, TTX-MC138, targets microRNA-10b (miRNA-10b), a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include two solid tumor programs such as TTX-siPDL1, a small interfering RNA (siRNA)based modulator of programmed death-ligand 1 (PD-L1), and TTX-siLin28b, a siRNA-based inhibitor of RNA-binding protein LIN28B. Its TTX platform is modular by design, both at the level of the core nanoparticle and at the therapeutic loading.

Price: Delayed
$1.26

Day's Change: -0.0008 (-0.06%)

Bid: --

Ask: --

B/A Size: --

Day's High: 1.26

Day's Low: 1.26

Volume (Light) Today's volume of 1,570 shares is on pace to be much lighter than RNAZ's 10-day average volume of 56,738 shares.: 1,570

There is no peer information for RNAZ.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.